Jointown Pharmaceutical Group invested 0.673 billion to participate in the restructuring, planning to "take control" of Special Treat Meigu and increase investment in medical aesthetics?| Quick read of the announcement.

① Jointown Pharmaceutical Group plans to invest 0.673 billion yuan to participate in the restructuring of Aoyuan Meigu; ② In recent years, Jointown Pharmaceutical Group's medical aesthetics business has grown rapidly and has established partnerships with many domestic medical aesthetics giants, clearly indicating an intention to strengthen this sector.

cls.cnApr 23 11:58 ET

Bidding farewell to the "Ten Thousand Stores Era," China National Accord Medicines Corporation's retail Sector reported a net loss exceeding 1.1 billion yuan | Interpretations.

① In 2024, both revenue and Net income of China National Accord Medicines Corporation have declined, with the retail Sector turning to a loss year-on-year. ② Within half a year, the total number of Guoda Pharmacy stores sharply decreased to 9,569, with over 1,200 directly-operated stores closed.

cls.cnApr 7 10:56 ET

Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.

In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.

cls.cnApr 6 20:17 ET

It is proposed to set aside a goodwill impairment provision of nearly 0.9 billion yuan. China National Accord Medicines Corporation's revenue and net profit are expected to decline in 2024 | Quick Announcement.

① Due to the combined impact of intensified market competition and other factors, China National Accord Medicines Corporation expects a decline in both revenue and Net income for 2024. ② The company plans to make an impairment provision totaling 1.094 billion yuan for credit impairment losses and asset impairment losses.

cls.cnMar 17 10:13 ET

A large number of consultations! The benefits of childcare subsidies continue to be released, and Assisted Reproduction companies are looking forward to a "combination punch."

① Recently, policies favorable for child-rearing have emerged from both central and local governments, with some regions even offering substantial monetary incentives to encourage childbirth. ② Industry experts pointed out to reporters at Caijing that the introduction of child-rearing subsidy policies can, to some extent, reduce the burden and concerns for young couples regarding childbirth. ③ Insiders from Assisted Reproduction companies have expressed that measures such as promoting cultural awareness of male responsibility in child-rearing are also highly anticipated in the industry.

cls.cnMar 17 01:44 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET